Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

HALOZYN Form 4 May 23, 20	1E THERAPEUT 07	TICS INC	-							
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940						N OMB Number: Expires: Estimated burden hou response	Number: 3235-028 Expires: January 31 Estimated average burden hours per response 0.			
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> Kennard Don A			2. Issuer Name and Ticker or Trading Symbol HALOZYME THERAPEUTICS INC [HALO]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
				of Earliest T Day/Year) 2007	ransaction	1	Director X Officer (g below) Vice Pro		% Owner ner (specify ory Aff	
				. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Tal	ole I - Non-I	Derivativ	e Securities	Acquired, Disposed	of or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deema Execution any (Month/Da	ed Date, if	3. Transactio Code (Instr. 8) Code V	4. Secur nAcquire Dispose (Instr. 3,	(A) (A) (A) (A) (A) (A)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Re	eport on a separate lin	e for each cla	ass of sec	curities bene	Pers infor requ	ons who re mation con ired to resp	or indirectly. spond to the collection tained in this form ond unless the for ently valid OMB co	m are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Code	5. orNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	;	Date	Amou Under Secur	rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Owne Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Edgar Filing: HALOZYME THERAPEUTICS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships						
reporting of the runner runner cost	Director	10% Owner	Officer	Other			
Kennard Don A C/O HALOZYME THERAPEUTICS, INC. 11588 SORRENTO VALLEY RD., SUITE 17 SAN DIEGO, CA 92121			Vice President, Regulatory Aff				
Signatures							
/s/ Don A. 05/23/2007							

Kennard

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, *see* Instruction 4(b)(v). *
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Remarks:

The company's Board of Directors determined on February 5, 2007 that Mr. Kennard was no longer an "officer" for the purpose

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.